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Adenosine, a purine nucleoside generated by the dephosphorylation of adenine
nucleotides, is a potent endogenous physiologic and pharmacologic regulator of many
functions. Adenosine was first reported to inhibit the inflammatory actions of neutrophils
nearly 30 years ago and since then the role of adenosine and its receptors as feedback regu-
lators of inflammation has been well established. Here we review the effects of adenosine,
acting at its receptors, on neutrophil and monocyte/macrophage function in inflammation.
Moreover, we review the role of adenosine in mediating the anti-inflammatory effects
of methotrexate, the anchor drug in the treatment of Rheumatoid Arthritis and other
inflammatory disorders.
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INTRODUCTION
The nucleoside adenosine is a potent physiologic and pharmaco-
logic regulator that is produced by cells in response to stress by
breakdown of adenosine triphosphate (ATP) (Hasko and Cron-
stein, 2004; Sitkovsky et al., 2004; Hasko et al., 2005, 2008). ATP
is broken down both intracellularly and extracellularly to gener-
ate adenosine (Figure 1). Intracellular adenosine is exported from
cells via equilibrative nucleoside transporters or during apoptosis
or necrosis. ATP and its degradation product adenosine diphos-
phate (ADP) are released from cells through a variety of mecha-
nisms, including membrane damage, through connexin/pannexin
and other channels, and through protein or hormone-transporting
vesicles. When ATP and ADP are released, the phosphate groups
of extracellular ATP and ADP are sequentially hydrolyzed, first
by ecto-nucleoside triphosphate diphosphorylases (NTPDases,
including CD39) and then by ecto-5′-nucleotidase (Ecto-5′NTase,
CD73) (Yegutkin, 2008).
Extracellular levels of adenosine can rise from low nano-
molar to micro-molar concentrations in response to stress (Hasko
et al., 2008). Adenosine regulates cell function through liga-
tion of adenosine receptors, which consist of a family of four
cell surface 7-transmembrane receptors (A1R, A2AR, A2BR, and
A3) (Linden, 2001). The activation of A1 and A3 receptors
leads to decreased intracellular cyclic adenosine monophosphate
(Gallardo-Soler et al., 2008) levels by coupling to pertussis toxin-
inhibited Gi-coupled signal transduction proteins. A2A recep-
tors are GαS- or Gαolf-linked receptors that activate adenylyl
cyclase, increase cAMP, and activate protein kinase A (PKA) and
Epac1/2which activate their own signaling cascades to regulate
cellular function. Interestingly, A2A receptors can also signal in a
G protein-independent manner. A2B receptors can signal through
both GαS and Gq proteins.
ADENOSINE AND THE SIGNS OF INFLAMMATION
Classically, inflammation is characterized by rubor (redness),
tumor (swelling), calor (heat), and functio laesa (loss of function).
These manifestations of inflammation result principally from vas-
cular dilatation and leakage and, although a large number and
variety of mediators are involved in inflammation it is likely that
adenosine, released at sites of tissue injury, plays a role in the patho-
genesis or regulation of these signs. Adenosine, acting primarily
at A2A receptors, has long been known to be a potent vasodila-
tor (Drury and Szent-Gyorgi, 1929) and this is the basis for use of
adenosine and adenosine A2A receptor agonists for pharmacologic
stress testing. Thus, it is likely adenosine release at inflamed sites
contributes to the erythema (rubor) and resulting heat loss (calor)
associated with inflammation. Interestingly, diminished produc-
tion of adenosine leads to dramatic vascular leakage resulting from
diminished activation of adenosine A2B receptors on the vascular
endothelium (Thompson et al., 2004; Eckle et al., 2008) suggest-
ing that the adenosine released at inflamed sites diminishes the
swelling (tumor) that is so prominent at inflamed sites.
ADENOSINE INHIBITS RECRUITMENT AND ACTIVATION OF
NEUTROPHILS
Neutrophils are recruited to inflamed sites by a combination
of chemokines and adhesive interactions between leukocytes
and the vascular endothelium. Adenosine diminishes inflamma-
tion by diminishing leukocyte recruitment; adenosine inhibits
stimulated neutrophil adhesion to the vascular endothelium
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FIGURE 1 |The effect of methotrexate on adenosine release.
Methotrexate is actively transported into the cell where it is
polyglutamated; MTX polyglutamate is a potent inhibitor of AMP
deaminase. Accumulation of AICAR, an intermediate metabolite in de novo
purine biosynthesis, leads to enhanced release of adenine nucleotides
which are released into the extracellular space and converted to adenosine.
MTXglu, methotrexate polyglutamates; DHFglu, dihydrofolate
polyglutamates; AICAR, aminoimidazole carboxamidoribonucleotide;
FAICAR, formyl AICAR; RFC1, reverse folate carrier 1; ADA, adenosine
deaminase; AK, adenosine kinase; NTPDase, nucleoside triphosphate
phosphohydrolase; ecto-5′NT, ecto-5′nucleotidase.
(Cronstein et al., 1986) and neutrophil-mediated injury to the
endothelium. Adenosine receptor stimulation diminishes neu-
trophil adhesion to the endothelium by inhibiting both selectin-
and integrin-mediated adhesive events (Cronstein et al., 1992;
Bullough et al., 1995; Bouma et al., 1996; Sullivan et al., 2004). Pre-
sumably these same mechanisms apply to recruitment of other cell
types to inflamed sites as well. Although having noted these anti-
inflammatory effects of adenosine it has recently been reported
that neutrophils release ATP which is converted to adenosine extra-
cellularly and the adenosine binds to A3 receptors to promote
chemotaxis and loss or inhibition of A3 receptors markedly reduces
leukocyte recruitment to sites of bacterial infection (Chen et al.,
2006). Other studies suggest that the A3 receptor-mediated effects
on neutrophil recruitment are more selective and may not be
important for recruitment to other chemoattractants (Montesinos
et al., 2006).
Adenosine diminishes stimulated neutrophil production of
oxygen radicals and other potentially deleterious mediators
(Reviewed in Taylor et al., 2005). Moreover, adenosine, act-
ing primarily at A2A receptors inhibits phagocytosis of parti-
cles (Reviewed in Taylor et al., 2005). Although cAMP medi-
ates many of the downstream effects of adenosine A2A recep-
tors via activation of PKA there have been reports that cAMP-
PKA-independent mechanisms mediate inhibition of neutrophil
activation by adenosine A2A receptors.
ADENOSINE AND CLASSICAL MACROPHAGE ACTIVATION
Macrophages are best known for initiating an effective innate
immune response against microbes by recognizing pathogen-
associated molecular patterns (PAMPs) through pattern-
recognition receptors (PRRs) (Pozzi et al., 2005). Following
phagocytosis, macrophages destroy most micro-organisms. By
producing diverse molecules and presenting antigens to T cells,
macrophages in addition to dendritic cells, orient the adaptive
immune response leading to the expansion and differentiation
of lymphocytes specific for invaders or cancer cells (Gordon and
Taylor, 2005; Preynat-Seauve et al., 2006).
Macrophages comprise a heterogeneous population of cells,
and show bewildering functional plasticity in response to dynamic
micro-environmental cues. Macrophage heterogeneity arises as
macrophages differentiate from immature monocyte precursors
or yolk-sac macrophages (Mills et al., 2000; Kuroda et al., 2002;
Mosser, 2003; Murray and Wynn, 2011). In a conscious parallel
with T helper (Th)1 and Th2 lymphocytes, macrophages have been
classified into M1 and M2 phenotypes. M1 or “classical” activation
of macrophages is induced by toll-like receptor (TLR) agonists,
either with or without the Th1 cytokine interferon (IFN)-γ, and
results in an inflammatory phenotype characterized by expression
of a series of inflammatory cytokines and chemokines, including
tumor necrosis factor (TNF)-α, interleukin (IL)-1-β, IL-6, IL-12,
and macrophage inflammatory protein (MIP)-1α (Mosser and
Edwards, 2008; Biswas and Mantovani, 2010). M1 macrophages
are strong promoters of Th1 immune responses (Hasko et al.,
2000) and have anti-proliferative and cytotoxic activities, which
result from their ability to produce reactive oxygen and nitrogen
species, such as hydrogen peroxide, superoxide, nitric oxide (NO),
and peroxynitrite, and pro-inflammatory cytokines.
The role of adenosine in regulating classical macrophage
activation has been studied in detail. As such, adenosine has
been shown to be a broad inhibitor of the pro-inflammatory
consequences of classical macrophage activation. The anti-
inflammatory effects of adenosine on M1 macrophages include
suppression of cytokine/chemokine production (Hasko et al.,
1996, 1998, 2007; Szabo et al., 1998; Xaus et al., 1999; Sipka
et al., 2005, 2007; Ryzhov et al., 2008; Koscso et al., 2012) and
NO production (Csoka et al., 2007a; Ryzhov et al., 2008). In con-
trast to the suppressive effect of adenosine on the production of
pro-inflammatory mediators, adenosine augments production of
the anti-inflammatory cytokine IL-10 by M1 macrophages. The
current consensus is that the regulatory effects of adenosine on
M1 macrophages are mediated predominantly by A2A receptors
(Hasko et al., 1996, 2009; Pinhal-Enfield et al., 2003; Nemeth et al.,
2005; Kreckler et al., 2006; Csoka et al., 2007b; Chen et al., 2009;
Wilson et al., 2009; Belikoff et al., 2011). For example, using A2A
receptor deficient mice combined with pharmacologic approaches,
it has been shown that adenosine inhibits TNF-α, IL-6, and IL-
12 release and augments IL-10 production by lipopolysaccharide
(LPS)- or bacteria-activated macrophages mostly through A2A
receptors (Nemeth et al., 2005; Hasko et al., 2007; Kara et al.,
2010a). Although, A2B receptors have been overshadowed by A2A
receptors as the primary adenosine receptors shaping the function
of M1 macrophages, there is growing evidence that A2B recep-
tors can also become operational in regulating M1 macrophage
function. In this context, we recently showed that A2B receptors
but not A2A receptors augment LPS-induced IL-10 production by
RAW264.7 macrophages, which express high levels of A2B recep-
tors and low levels of A2A receptors (Pinhal-Enfield et al., 2003).
Moreover, adenosine can suppress LPS-induced TNF-α produc-
tion even in A2A receptor deficient mice, and this effect is mediated
by A2B receptors (Kara et al., 2010a). A1 adenosine receptors and
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A3 receptors are expressed at much lower levels on the surface
of macrophages and their role in regulating macrophage function
remains incompletely understood (Hasko et al., 1996).
Studies utilizing A1 receptor deficient mice recently showed
that A1 receptors play a critical role in osteoclast development
from monocytic precursors (Merrill et al., 1995). Interestingly, A1
receptors also regulate fusion of human peripheral blood mono-
cytes into giant cells in vitro as well although the mechanism for
this regulation has not been fully established (Merrill et al., 1997;
Hasko and Pacher, 2012). Genetic studies have yet to confirm the
role of A3 receptors in governing macrophage function (Nelms
et al., 1999).
ADENOSINE AND ALTERNATIVE MACROPHAGE ACTIVATION
M2 or “alternatively activated” macrophages were originally
described as macrophages induced by the Th2 cytokines IL-4 and
IL-13. The effects of IL-4 and IL-13 on macrophages partially
overlap because they use dimeric receptors that share the IL-4
receptor (IL-4R)α subunit. In contrast, the differences between
signaling by IL-4 and IL-13 stem from the fact that while IL-4
is able to activate both the IL-4Rα/common γ chain and IL-
4Rα/IL-13Rα dimers, IL-13 can only activate the latter complex.
The intracellular signaling pathways are incompletely character-
ized and involve members of the Janus-activated kinase (JAK)
and signal transducer and activator of transcription (STAT) fam-
ily, especially STAT6. In addition to STAT6 (Gray et al., 2005),
recent studies have identified CCAAT-enhancer-binding protein
(C/EBP)β (Pauleau et al., 2004; Albina et al., 2005; Ruffell et al.,
2009), cAMP response element-binding protein (CREB) (Ode-
gaard et al., 2007), peroxisome proliferator-activated receptor
(PPAR)γ (Gallardo-Soler et al., 2008; Satoh et al., 2010; Szanto
et al., 2010), IFN regulatory factor (IRF)4 (El Chartouni et al.,
2010; Liao et al., 2011), Krüppel-like factor 4 (KLF4) (Takeda
et al., 2010), hypoxia-inducible factor-2 (HIF-2) (Pello et al.,
2012), and c-MYC (Sica and Mantovani, 2012) as contributors
to the transcriptional response driving M2 macrophage activa-
tion. Hallmark M2 markers include arginase-1, tissue inhibitor of
metalloproteinases (TIMP)-1, macrophage galactose-type C-type
lectin (mgl)-1, IL-4Rα, Ym1, and resistin-like molecule (RELM)α
(Anthony et al., 2006). Increasingly, activation of multiple markers
is used to unequivocally identify M2 macrophages in the context
of responses to different antigens (Chen et al., 2012).
M2 macrophages are elicited following infection with multi-
cellular parasites, and can lead to an inflammatory response qual-
itatively different from and capable of downregulating harmful
Th1-type inflammatory responses. Recent studies have suggested
that increased M2 macrophage arginase activity during helminth
infections is an important element in the control and expulsion
of worms (Hesse et al., 2001; Gordon, 2003; Edwards et al., 2006).
M2 macrophages contribute to the control of inflammation and
can mediate enhanced wound healing through arg-1-mediated
production of collagen and insulin-like growth factor 1 (IGF-1),
and by contributing to the clearance of cellular debris through
scavenger receptors (Gordon, 2003; Anthony et al., 2006). The
immunoregulatory/protective, rather than tissue damaging, role of
M2 macrophages is also exemplified by the fact that they are abun-
dant in healthy tissues that are associated with naturally immune
suppressed states, such as placenta, lung, and other immuno-
logically privileged sites (Noel et al., 2004). In contrast to their
protective effects in acute inflammation, it has been proposed that
M2 macrophages activated by IL-4 and IL-13 during asthma and
chronic obstructive pulmonary disease contribute significantly to
airway remodeling and lung fibrosis leading to lung dysfunction
(Mantovani et al., 2004; Van Ginderachter et al., 2006; Martinez
et al., 2008; Csoka et al., 2012). Additionally, M2 macrophages
have also been shown to be hijacked by tumor cells to function
as suppressors of anti-tumor T cell responses and stimulators of
tumor angiogenesis (Martinez et al., 2008; Koroskenyi et al., 2011).
Based on these observations, M2 macrophages have been pro-
posed as an emerging therapeutic target for a variety of disease
states.
We have recently discovered that adenosine strongly promotes
IL-4/IL-13-induced M2 macrophage activation in vitro, as indi-
cated by upregulation of the arginase-1, TIMP-1, and mgl-1 (Bar-
czyk et al., 2010). Our studies, utilizing both pharmacological
approaches and macrophages from adenosine receptor deficient
and wild type (WT) mice, indicate that A2B adenosine receptors,
and to a lesser degree other adenosine receptors, are required for
mediating the stimulatory effect of adenosine on IL-4-induced
M2 macrophage activation. Our data also indicate that the stimu-
latory effect of adenosine receptor activation on M2 macrophage
development is mediated by the transcription factor C/EBPβ, but
not STAT6 or CREB (Barczyk et al., 2010).
While the designation M2 usually denotes macrophages acti-
vated by IL-4 or IL-13, M2 macrophages can also be induced by
other anti-inflammatory stimuli, which include immune com-
plexes, and heterogeneous deactivating mediators such as apop-
totic cells, glucocorticoids, and IL-10 (Kular et al., 2012). Thus,
IL-4/IL-13-activated macrophages are also called M2a, immune
complex-activated macrophages are referred to as M2b, and
macrophages activated by apoptotic cells, glucocorticoids, and
IL-10 are termed M2c. In macrophages phagocytosing apoptotic
cells, adenosine released endogenously activates A2A receptors
and inhibits the generation of the pro-inflammatory chemokines
MIP-2 and cytokine-induced neutrophil-attracting chemokine
(KC) (Kara et al., 2010b). Moreover, glucocorticoids promote
survival of anti-inflammatory monocytes via upregulation and
autocrine activation of A3 adenosine receptors (Mediero et al.,
2012a). Together, in macrophages exposed to apoptotic cells and
glucocorticoids adenosine switches macrophage phenotype from
pro-inflammatory to anti-inflammatory (Nelms et al., 1999).
ADENOSINE AND MYELOID/MONOCYTE-DERIVED
SYNCYTIAL CELLS (OSTEOCLASTS AND GIANT CELLS)
Myeloid precursors can, in response to M-CSF and RANKL, dif-
ferentiate into osteoclasts, multinucleated giant cells that mediate
bone resorption (Mediero et al., 2012b). Studies utilizing A1 recep-
tor deficient mice recently showed that A1 receptors play a critical
role in osteoclast development from monocytic precursors and
bone resorption (Ernst et al., 2010; McNally and Anderson, 2011).
In contrast to A1 adenosine receptors, A2A receptors inhibit osteo-
clast differentiation and function (Deaglio et al., 2007) and A2A
receptor stimulation has been shown to inhibit wear particle-
induced osteolysis, a form of inflammatory bone destruction
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Table 1 | Cellular expression of adenosine receptors.
A1 receptor A2A receptor A2B receptor A3 receptor
Neutrophils Diminished adhesion, activation Stimulates chemotaxis
M1
macrophages
Inhibit phagocytosis, inflammatory cytokine
production, increase IL-10
Stimulates IL-10
M2
macrophages
Stimulates M2 macrophage differentiation
Production of pro-angiogenic factors
Lymphocytes Inhibits TH17 differentiation
Stimulates TReg differentiation
Osteoclasts
and giant cells
Promotes osteoclast differentiation Inhibits osteoclast differentiation
Stimulates giant cell formation
resulting from particulates shed from joint prostheses (Chalmin
et al., 2012).
Similar to osteoclasts, in response to IFN-γ or other stimuli,
monocytes will fuse to form multinucleated giant cells, hallmarks
of responses to foreign bodies and such diseases as Sarcoidosis
(Semenza, 2010). Interestingly, A1 receptors also regulate fusion
of human peripheral blood monocytes into giant cells in vitro as
well although the mechanism for this regulation has not been fully
established (Merrill et al., 1997; Hasko and Pacher, 2012). Genetic
studies have yet to confirm the role of A3 receptors in governing
macrophage function (Nelms et al., 1999).
ADENOSINE AND T CELLS
Forkhead box P3 (FOXP3)-expressing regulatory T (Treg) cells
are crucial in the maintenance of immunological self-tolerance
and in the regulation of immune responses. CD39 and CD73 are
expressed on the surface of Foxp3+ Tregs and are increasingly used
as markers of Tregs (Leibovich et al., 2002). Deaglio et al. (2007)
and Adair (2005) showed that CD39 and CD73 on the surface of
Tregs produce adenosine, which mediates a substantial portion of
the anti-inflammatory and immune regulatory effects of Tregs by
engaging A2A receptors on effector T cells. More recently, Th 17
cells were also shown to express CD39 and CD73, which, by pro-
ducing adenosine, suppress both CD4+ and CD8+ T cell effector
functions (Hasko et al., 2009). The expression of both CD39 and
CD73 on Th17 cells was upregulated by IL-6 and TGF-β, factors
that are crucial for Th17 cell development (Ramanathan et al.,
2009).
ADENOSINE AND THE ANGIOGENIC SWITCH IN
MACROPHAGES
Vascular endothelial growth factor (VEGF) is a potent stimulator
of angiogenesis and is crucial for the differentiation of endothe-
lial cells during vasculogenesis, and for the outgrowth of new
capillaries from pre-existing blood vessels (Ramanathan et al.,
2007). VEGF is thus an important component of tissue repair,
and is critical for the resolution of inflammation and wound
healing. Macrophages are prominent producers of VEGF dur-
ing the resolution of inflammation and wound healing. There is
a plethora of evidence demonstrating that adenosine promotes
angiogenesis, in a large part, by increasing macrophage VEGF
production (Murphree et al., 2005; Csoka et al., 2007b; Ernens
et al., 2010). It has been shown that adenosine stimulation of
A2A receptors on TLR-activated macrophages results in a switch
from the production of inflammatory cytokines such as TNF-α
and IL-12, to the production of anti-inflammatory and angio-
genic factors, including IL-10 and VEGF (Ohta and Sitkovsky,
2001; Gessi et al., 2010) and we termed this process angiogenic
switch (Csoka et al., 2007b). This model provides a sequential
pathway whereby macrophages initially mediate inflammation
through TLR-dependent activation to an M1 phenotype, but are
then switched into an angiogenic phenotype by adenosine gen-
erated in response to hypoxia/ischemia within the wound area.
In addition, the initial activation of macrophages by TLR ago-
nists, which markedly induce expression of adenosine A2A and
A2B adenosine receptors, primes these macrophages to respond
to increased local levels of extracellular adenosine (Chan and
Cronstein, 2010; Gessi et al., 2010). It is noteworthy that while
A2A (Csoka et al., 2007b) and A2B (unpublished data) recep-
tors mediate the angiogenic switch in murine macrophages, the
adenosine-mediated increase in VEGF secretion by human mono-
cytes is mediated by A2A, A2B, and A3 receptors (Varani et al., 2009,
2011).
ADENOSINE AND ADENOSINE RECEPTORS IN
INFLAMMATORY DISEASES
From its initial identification as an anti-inflammatory ligand
adenosine was thought to be an important endogenous feedback
regulator of inflammation and tissue injury. Nonetheless, the first
actual demonstration that adenosine, acting at A2A receptors, was
an endogenous anti-inflammatory agent had to wait until the
development of adenosine receptor knockout mice. Liver injury
in response to concanavalin A, a model for viral hepatitis, was
markedly enhanced in the absence of adenosine A2A receptors
(Khoa et al., 2006), consistent with the hypothesis that, at least in
the liver, increased adenosine release at inflamed sites suppresses
inflammation and inflammatory injury.
However, making use of adenosine as an anti-inflammatory
agent has remained more of a challenge due to the myriad other
effects of adenosine acting at A2A and other adenosine recep-
tors, e.g., hypotension. Interestingly, it is now clear that low-dose
methotrexate, the anchor drug for the treatment of rheumatoid
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arthritis, mediates its anti-inflammatory effects via promotion of
adenosine release at inflamed sites (Reviewed in Khoa et al., 2001).
The “immunosuppressive” effects of methotrexate-mediated inhi-
bition of T cell proliferation are unlikely to account for the effects
of methotrexate administered at doses well below those required
to inhibit cellular proliferation (15–20 mg/week) and methotrex-
ate is usually accompanied by folic acid or folinic acid supple-
mentation to prevent toxicity without diminishing efficacy. The
effects of adenosine, described above, on lymphocyte function
provide a better explanation for the immunosuppressive effects
of methotrexate, as used to treat Rheumatoid Arthritis (Khoa
et al., 2001). Because adenosine receptor expression is increased
on leukocytes in patients with Rheumatoid Arthritis (Levy et al.,
2006; Hesdorffer et al., 2012), most likely the result of exposure
of these cells to high concentrations of TNFα, a cytokine previ-
ously demonstrated to increase adenosine A2A receptor expres-
sion and function (Smail et al., 1992; Thammavongsa et al.,
2009), it is likely that these patients are “primed” to respond to
increased adenosine concentrations resulting from methotrexate
therapy.
ADENOSINE AND AGING
Immunologic and inflammatory responses are blunted at the
beginning and end of life leading to increased susceptibilities
to infection for neonates and the elderly. Recent work has sug-
gested that adenosine and its receptors play a role in suppress-
ing responses to infection. Levy et al. (2006) have reported that
monocyte/macrophages from neonates are much more sensitive
to adenosine A3 receptor-mediated suppression of inflammatory
responses (TNF production) than those from adults. In con-
trast, lymphocytes from the elderly release increased amounts of
adenosine leading to suppression of T cell responses (Hesdorffer
et al., 2012).
ADENOSINE IS A VIRULENCE FACTOR PRODUCED BY
PATHOGENS
It is not uncommon for invasive pathogens to take advantage
of mammalian mechanisms for suppression of host responses
to promote spread or survival of the infecting organism. Thus,
it was not surprising to find that Candida albicans hyphae
release adenosine which suppresses neutrophil-mediated killing
of the organism (Smail et al., 1992). More recent studies have
demonstrated that Staphylococcus aureus also produce adeno-
sine to avoid killing by the host as well (Thammavongsa et al.,
2009). Thus, adenosine, produced by invasive organisms can pro-
mote spread of the organism by suppressing host killing of the
bacteria.
CONCLUSION
Adenosine is a potent endogenous anti-inflammatory agent that
regulates the function of inflammatory cells via interaction with
specific receptors expressed on these cells (Table 1). Already known
as an endogenous regulator of inflammation, adenosine also medi-
ates the anti-inflammatory effects of methotrexate, one of the most
widely used anti-inflammatory drugs.
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